A Case-Based Exploration of Current and Future Directions in Myelofibrosis — Where We Are, Where We’re Going

Join us on Friday, December 11^th from 3:15 PM to 5:15 PM central time (4:15 PM to 6:15 PM eastern time).

MODULE 1: Current Clinical Decision-Making for Patients with Myelofibrosis (MF) in the Absence of Severe Cytopenias

MODULE 2: Managing MF in Patients with Anemia

MODULE 3: Managing MF in Patients with Thrombocytopenia

MODULE 4: Novel Approaches for MF Potentially Nearing the Clinic

MODULE 5: Other Promising Novel Agents Under Investigation in MF

Target Audience
This activity is intended for hematologists, medical oncologists, hematology-oncology fellows and other healthcare providers involved in the treatment of myelofibrosis (MF).

Learning Objectives
At the conclusion of this activity, participants should be able to

• Use an understanding of disease biology and natural history to effectively counsel patients diagnosed with MF regarding their long-term prognosis.
• Analyze how age, performance status and other biological and disease-related factors affect the decision to initiate therapy and the subsequent selection of treatment for patients with primary and secondary MF.
• Appraise available research informing the safety and efficacy of approved JAK inhibitors for patients with MF, including those with anemia, thrombocytopenia or compromised renal function, and personalize treatment recommendations based on this information.
• Evaluate published research findings with JAK inhibitors for MF and anemia to optimize decision-making for this patient population.
• Review available research data with and the current clinical role of novel JAK inhibitors for patients with MF and severe thrombocytopenia.
• Understand the biological rationale for the inhibition of exportin 1 (XPO1) in patients with MF, and reflect on available and emerging research findings with XPO1 inhibitors in combination with JAK inhibition as front-line treatment.
• Recall available research findings with combination regimens incorporating JAK inhibitors and other novel investigational agents, and consider the potential role of these emerging approaches.
• Recognize the spectrum, frequency and severity of side effects associated with JAK inhibitors and other therapies for MF, and implement a plan of care to recognize, prevent and manage toxicities.
• Assess the mechanism of action, available research findings, and ongoing investigation of other novel agents in MF, and consider the potential clinical application of these approaches.

CE Credit
CME credit information will be provided to each participant at the conclusion of the activity.

Accreditation Statement
Research To Practice is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

Credit Designation Statement
Research To Practice designates this live activity for a maximum of 2 AMA PRA Category 1 Credits^TM. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Privacy Policy
Personal information and data sharing: Research To Practice aggregates deidentified user data for program-use analysis, program development, activity planning and site improvement. We may provide aggregate and deidentified data to third parties, including commercial supporters. We do not share or sell personally identifiable information to any unaffiliated third parties or commercial supporters. Please see our privacy policy at ResearchToPractice.com/Privacy-Policy for more information.

Unlabeled/Unapproved Uses Notice
This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the Food and Drug Administration. Research To Practice does not recommend the use of any agent outside of the labeled indications. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications and warnings. The opinions expressed are those of the presenters and are not to be construed as those of the provider or grantors.

Content Validation and Disclosures
Research To Practice (RTP) is committed to providing its participants with high-quality, unbiased and state-of-the-art education and adheres to the ACCME’s Standards for Integrity and Independence in Accredited Continuing Education. Any individuals in a position to control the content of an accredited continuing education activity, including faculty, planners, reviewers and others, are required to disclose all relevant financial relationships with ineligible entities (commercial interests). All relevant financial relationships will have been mitigated prior to the commencement of this activity. In addition, all activity content is reviewed by RTP scientific staff and an external, independent physician reviewer for fair balance, scientific objectivity of studies referenced and patient care recommendations. Faculty disclosures to be announced.

FACULTY
To be announced.

MODERATOR
To be announced.

Research To Practice CME Planning Committee Members, Staff and Reviewers
Planners, scientific staff and independent reviewers for Research To Practice have no relevant financial relationships to disclose.

Supporters
This activity is supported by educational grants from Bristol Myers Squibb, Geron Corporation, GSK, Karyopharm Therapeutics, and Novartis.

Sheraton New Orleans Hotel
500 Canal Street
New Orleans, LA 70130
Hotel Phone: (504) 525-2500

Meeting Room
Napoleon Ballroom C/D — Third floor

Directions
The Sheraton New Orleans Hotel is located 0.9 miles (15-minute walk) from the New Orleans Ernest N Morial Convention Center, where the 2026 ASH Annual Meeting is taking place.

Program slides will be made available prior to the start of the session.

Registration to attend virtually is open to all professionals.

Please click the link to register for this live event directly on Zoom. Once you register, Zoom will send a confirmation email with your individual link to access the event. Please keep that confirmation email handy. If you do not receive it, contact our support team at meetings@researchtopractice.com.

To ensure seating and meal service, please check in at our onsite registration desk before the start of the meeting. We cannot guarantee seating after the start of the program.

Photography and/or video recording may be taken during the educational program by Research To Practice and used in future educational offerings.

Research To Practice fully complies with the legal requirements of the ADA. If you require any physical, dietary or other accommodations, please call us at (800) 233-6153 before the event.

If you have any questions, please feel free to contact us via email at Meetings@ResearchToPractice.com, or call (800) 233-6153.